CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Other than Enbrel, which increased 14 percent in sales on the year to $5.36 billion in 2015, two other Amgen blockbuster drugs had modest declines. Neulasta helps the body make white blood cells after ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer ...